The agreement with the Hebrew University of Jerusalem will allow ECO to develop a novel formulation of florfenicol, for the treatment of respiratory diseases in pigs. Subject to successful development, the programme could offer an exciting portfolio addition to Aivlosin®, offering single-dose, injectable administration and a complementary spectrum of anti-microbial activity. We reiterate our positive stance.
03 Dec 2018
Anti-microbial pipeline expansion
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Anti-microbial pipeline expansion
ECO Animal Health Group plc (EAH:LON) | 94.0 0 0.0% | Mkt Cap: 63.7m
- Published:
03 Dec 2018 -
Author:
Jens Lindqvist -
Pages:
3
The agreement with the Hebrew University of Jerusalem will allow ECO to develop a novel formulation of florfenicol, for the treatment of respiratory diseases in pigs. Subject to successful development, the programme could offer an exciting portfolio addition to Aivlosin®, offering single-dose, injectable administration and a complementary spectrum of anti-microbial activity. We reiterate our positive stance.